In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial
- PMID: 34849920
- PMCID: PMC9115328
- DOI: 10.1093/humrep/deab243
In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial
Abstract
Study question: Does in vitro maturation (IVM) result in non-inferior cumulative live birth rates compared to those after standard in vitro fertilization (IVF) in infertile women with polycystic ovary syndrome (PCOS)?
Summary answer: One cycle of IVM, without any stimulation, was inferior to one cycle of standard IVF in women with PCOS in terms of 6-month cumulative live birth rates, when choosing single vitrified-warmed blastocyst transfer.
What is known already: IVM is an emerging alternative treatment for women with PCOS who need assisted reproductive technology. Since a minimal or even zero dose of gonadotropins are required in the IVM procedure, the occurrence of ovarian hyperstimulation syndrome (OHSS) is eliminated. Only one clinical trial comparing the pregnancy outcome between IVM with FSH priming and IVF has been reported. However, it is still unknown whether IVM treatment without any stimulation can offer a similar live birth outcome in women with PCOS as compared to that in women receiving the standard IVF procedure with ovarian stimulation.
Study design, size, duration: This single-centre, open-label randomized controlled non-inferiority trial in an academic infertility centre in China was performed between March 2018 and July 2019.
Participants/materials, setting, methods: Women aged 20-38 years with PCOS and infertility scheduled for their first IVF attempt were eligible. In total, 351 women were randomly allocated to receive one cycle of unstimulated IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol and hCG as ovulatory trigger (n = 176). A freeze-all and single blastocyst transfer strategy was used in both groups. The primary outcome was ongoing pregnancy (leading to live birth) within 6 months after randomization. A non-inferiority margin of 15% was considered.
Main results and the role of chance: The IVM procedure without additional gonadotropin resulted in a lower ongoing pregnancy (leading to live birth) within 6 months after randomization compared to standard IVF treatment (22.3% vs. 50.6%; rate difference -28.3%; 95% confidence interval [CI]: -37.9% to -18.7%). Moderate-severe OHSS did not occur in the IVM group, while in the IVF group, ten women (5.7%) had moderate OHSS and one woman (0.6%) had severe OHSS. There was no statistically significant difference in the occurrence of obstetric and perinatal complications.
Limitations, reasons for caution: The trial was conducted using an IVM protocol without additional stimulation in a single centre, which may limit its generalizability. In addition, a GnRH agonist trigger rather than hCG for IVF stimulation in women with PCOS would be more consistent with current clinical practice.
Wider implications of the findings: Although IVM is considered to be a convenient, inexpensive and safe alternative to IVF for women with PCOS, our results indicated that one cycle of IVM without any stimulation was inferior to one cycle of standard IVF in terms of the cumulative live birth rate. The inferiority of IVM without ovarian stimulation could be mainly due to the limitations in the developmental potential of embryos. Further IVM development should be tested and validated in a freeze-only and blastocyst transfer setting. Further RCTs are needed to evaluate the effectiveness and safety of other IVM protocols or multiple cycles of IVM compared to IVF.
Study funding/competing interest(s): This study was supported by the National Key Research and Development Program of China (2016YFC1000201 and 2018YFC1002104) and the National Science Foundation of China (81730038). B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). All other authors declare no competing interests.
Trial registration number: Clinicaltrials.gov NCT03463772.
Trial registration date: 29 January 2018.
Date of first patient’s enrolment: 16 March 2018.
Keywords: in vitro fertilization; in vitro maturation; live birth; polycystic ovary syndrome; randomized controlled trial.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
Similar articles
-
In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial.Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240. Hum Reprod. 2020. PMID: 32974672 Clinical Trial.
-
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.Hum Reprod. 2016 Jun;31(6):1253-64. doi: 10.1093/humrep/dew051. Epub 2016 Apr 8. Hum Reprod. 2016. PMID: 27060174 Clinical Trial.
-
The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.Hum Reprod. 2019 Jun 4;34(6):1055-1064. doi: 10.1093/humrep/dez060. Hum Reprod. 2019. PMID: 31111879
-
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD006105. doi: 10.1002/14651858.CD006105.pub4. Cochrane Database Syst Rev. 2020. PMID: 33347618 Free PMC article.
-
Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.Sci Rep. 2022 Mar 15;12(1):4456. doi: 10.1038/s41598-022-08400-z. Sci Rep. 2022. PMID: 35292717 Free PMC article.
Cited by
-
Live birth after letrozole as an adjunct to follicle-stimulating hormone versus follicle-stimulating hormone alone for ovarian stimulation in in vitro fertilisation cycles-study protocol for a randomised controlled trial.Trials. 2022 Apr 1;23(1):247. doi: 10.1186/s13063-022-06185-0. Trials. 2022. PMID: 35365197 Free PMC article.
-
Insights gained from a cleavage-stage embryo freeze-all policy in in vitro maturation cycles.J Assist Reprod Genet. 2025 Jun;42(6):1795-1804. doi: 10.1007/s10815-025-03469-7. Epub 2025 Apr 2. J Assist Reprod Genet. 2025. PMID: 40175788
-
Pro-cumulin addition in a biphasic in vitro oocyte maturation system modulates human oocyte and cumulus cell transcriptomes.Mol Hum Reprod. 2025 Jan 17;31(1):gaaf001. doi: 10.1093/molehr/gaaf001. Mol Hum Reprod. 2025. PMID: 39862403 Free PMC article.
-
EPAS1 expression contributes to maintenance of the primordial follicle pool in the mouse ovary.Sci Rep. 2024 Apr 16;14(1):8770. doi: 10.1038/s41598-024-59382-z. Sci Rep. 2024. PMID: 38627575 Free PMC article.
-
Minimising OHSS in women with PCOS.Front Endocrinol (Lausanne). 2025 Mar 13;16:1507857. doi: 10.3389/fendo.2025.1507857. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40182629 Free PMC article. Review.
References
-
- Belva F, Roelants M, Vermaning S, Desmyttere S, De Schepper J, Bonduelle M, Tournaye H, Hes F, De Vos M. Growth and other health outcomes of 2-year-old singletons born after IVM versus controlled ovarian stimulation in mothers with polycystic ovary syndrome. Hum Reprod Open 2020;2020:hoz043. - PMC - PubMed
-
- Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991;55:109–113. - PubMed
-
- Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013;99:1173–1181. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials